Tioga strikes Asian licensing deal for lead molecule
This article was originally published in Scrip
Executive Summary
Tioga Pharmaceuticals has licensed its potential irritable bowel syndrome (IBS) therapy asimadoline to Japan's Ono Pharmaceutical, for development and commercialisation in Japan, South Korea and Taiwan.